PDCD1 and cancer: This network meta-analysis of 26 randomized trials involving 5,982 ovarian cancer patients showed that cancer vaccines and dual immune checkpoint blockade achieved the best outcomes in overall and progression-free survival, while CTLA-4 inhibitors and cancer vaccines improved response rates, and PD-1 inhibitors demonstrated the greatest safety.